Real world treatment and outcomes in patients with EGFR mutation positive advanced non-small cell lung cancer: the Kent Cancer Network experience

Lung Cancer ◽  
2019 ◽  
Vol 127 ◽  
pp. S39
Author(s):  
V. Angelis ◽  
M. Fenton ◽  
S. Hunter ◽  
R. Shah
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Network

scholarly journals ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell lung cancer in real-world setting

2018 ◽  
Vol 10 (7) ◽  
pp. 4169-4177 ◽  
Author(s):  
Shirong Zhang ◽  
Lucheng Zhu ◽  
Xueqin Chen ◽  
Xiaochen Zhang ◽  
Enguo Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Egfr Mutation ◽  
Small Cell ◽  
Chinese Patients ◽  
Small Cell Lung ◽  
Mutation Status ◽  
Real World Setting

scholarly journals Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib

2019 ◽  
Vol 24 (8) ◽  
pp. 917-926 ◽  
Author(s):  
Kazuo Tamura ◽  
Toshihiro Nukiwa ◽  
Akihiko Gemma ◽  
Nobuyuki Yamamoto ◽  
Masaya Mizushima ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Egfr Mutation ◽  
Japanese Patients ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer

2020 ◽  
Author(s):  
Eric Nadler ◽  
Janet L Espirito ◽  
Melissa Pavilack ◽  
Bismark Baidoo ◽  
Ancilla Fernandes
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Service Use ◽  
Egfr Mutation ◽  
Symptom Burden ◽  
Small Cell ◽  
Small Cell Lung

Aim: To evaluate the real-world impact of brain metastases (BM) among patients with EGFR mutation-positive ( EGFRm) metastatic non-small-cell lung cancer (NSCLC). Materials & methods: This retrospective, observational matched cohort electronic health record study assessed adults with EGFRm metastatic NSCLC with/without BM. Results: Among 402 patients split equally between both cohorts (±BM), the majority were Caucasian (69%), female (65%) and with adenocarcinoma (92%). Overall symptom burden and ancillary support service use were higher and median overall survival from metastatic diagnosis was significantly shorter in BM patients (11.9 vs 16 months; p = 0.017). Conclusion: BM in EGFRm NSCLC patients can negatively impact clinical outcomes. New targeted therapies that can penetrate the blood–brain barrier should be considered for treating these patients.

scholarly journals Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib

2019 ◽  
Vol 24 (9) ◽  
pp. 1169-1169
Author(s):  
Kazuo Tamura ◽  
Toshihiro Nukiwa ◽  
Akihiko Gemma ◽  
Nobuyuki Yamamoto ◽  
Masaya Mizushima ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Egfr Mutation ◽  
Japanese Patients ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting

2019 ◽  
Vol 11 ◽  
pp. 175883591983637 ◽  
Author(s):  
Keunchil Park ◽  
Darren Wan-Teck Lim ◽  
Isamu Okamoto ◽  
James Chih-Hsin Yang
Keyword(s):  
Lung Cancer ◽  
Clinical Practice ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Clinical Studies ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line

Afatinib is an ErbB family blocker that is approved for the treatment of epidermal growth factor receptor ( EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal randomized clinical studies demonstrated that afatinib significantly prolonged progression-free survival compared with platinum-based chemotherapy (LUX-Lung 3, LUX-Lung 6), and with gefitinib (LUX-Lung 7), with manageable side effects. However, these results were derived from controlled studies conducted in selected patients and are not necessarily representative of real-world use of afatinib. To gain a broader understanding of the effectiveness and safety of first-line afatinib, we have undertaken a literature review of real-world studies that have assessed its use in a variety of patient populations. We focused on patients with uncommon EGFR mutations, brain metastases, or those of advanced age, as these patients are often excluded from clinical studies but are regularly seen in routine clinical practice. The available real-world studies suggest that afatinib has clinical activity, and is tolerable, in diverse patient populations in an everyday clinical practice setting. Moreover, consistent with LUX-Lung 7, several real-world comparative studies indicate that afatinib might confer better efficacy than first-generation EGFR tyrosine kinase inhibitors. Tolerability-guided dose adjustment, undertaken in 21–68% of patients in clinical practice, did not appear to reduce the efficacy of afatinib. Taken together, these findings provide further support for the use of afatinib as a treatment option in patients with EGFR mutation-positive NSCLC.

Sign in / Sign up

Export Citation Format

Share Document